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Glucose is the main energy substrate for the brain. There is now extensive evidence
indicating that the metabolic profile of neural cells with regard to glucose utilization
and glycolysis rate is not homogenous, with a marked propensity for glycolytic glucose
processing in astrocytes compared to neurons. Methylglyoxal, a highly reactive dicarbonyl
compound, is inevitably formed as a by-product of glycolysis. Methylglyoxal is a
major cell-permeant precursor of advanced glycation end-products (AGEs), which are
associated with several pathologies including diabetes, aging and neurodegenerative
diseases. In normal situations, cells are protected against methylglyoxal toxicity by
different mechanisms and in particular the glyoxalase system, which represents the most
important pathway for the detoxification of methylglyoxal. While the neurotoxic effects of
methylglyoxal and AGEs are well characterized, our understanding the glyoxalase system
in the brain is more scattered. Considering the high energy requirements (i.e., glucose) of
the brain, one should expect that the cerebral glyoxalase system is adequately fitted to
handle methylglyoxal toxicity. This review focuses on our actual knowledge on the cellular
aspects of the glyoxalase system in brain cells, in particular with regard to its activity in
astrocytes and neurons. A main emerging concept is that these two neural cell types have
different and energetically adapted glyoxalase defense mechanisms which may serve as
protective mechanism against methylglyoxal-induced cellular damage.
Keywords: methylglyoxal, neuron, astrocyte, triosephosphate, advanced-glycation end-products (AGEs),
glutathione
INTRODUCTION
The brain has high energy requirements and glucose is the main
energy substrate for the brain. About 20% of the oxygen con-
sumed by the human body are dedicated to cerebral functions
(Mink et al., 1981), yet the brain represents around only 2% of the
total body mass (Molina and DiMaio, 2012). Maintenance and
restoration of ion gradients dissipated by signaling processes such
as postsynaptic and action potentials, as well as uptake and recy-
cling of neurotransmitters, are the main processes contributing
to the high energy needs of the awake brain (Jolivet et al., 2009;
Harris et al., 2012; Hyder et al., 2013). For instance, it has been
estimated that glutamate-mediated neurotransmission is respon-
sible for most of the energy expended in the gray matter (Sibson
et al., 1998; Shulman et al., 2004; Hyder et al., 2006), highlight-
ing the close relationship between brain activity, glutamatergic
neurotransmission, energy requirements and glucose utilization.
While neurons have high energy requirements, astrocytes are
generally considered to account for around 20% of the awake
brain’s energy expenditure (Harris et al., 2012; Hyder et al.,
2013). Intriguingly, experimental evidence demonstrates that the
amount of glucose that astrocytes actually take up is dispro-
portionally high in comparison to their energy requirements.
For example, in acute cerebellar slices, the uptake of fluores-
cent glucose analogs is several-fold higher in Bergmann glia
than in Purkinje cells (Barros et al., 2009; Jakoby et al., 2014).
Nevertheless, one should mention that the stereospecificity of
such fluorescent glucose analogs has been questioned (Yamamoto
et al., 2011). In the resting rat brain, other studies have shown
that astrocytes are responsible for approximately half of glu-
cose uptake (Nehlig et al., 2004; Chuquet et al., 2010), and that
this proportion increases even further upon functional activa-
tion (Chuquet et al., 2010). Such observations may be seen as
paradoxical since neurons, not astrocytes, have the highest energy
needs. A simple explanation for such an apparent paradox is the
transfer of glycolysis-derived energy substrates from astrocytes to
neurons. For instance, according to the astrocyte-neuron lactate
shuttle (ANLS), glutamate uptake into astrocytes during synap-
tic activation (i.e., glutamatergic neurotransmission) stimulates
glucose uptake and aerobic glycolysis in astrocytes. Lactate pro-
duced through astrocytic aerobic glycolysis is then shuttled to
neurons where it is used to produce energy in the mitochon-
dria, i.e., lactate is converted to pyruvate which is then processed
in the tricarboxylic acid (TCA) cycle, hence bypassing neuronal
glycolysis (Magistretti, 2009; Bélanger et al., 2011a; Pellerin and
Magistretti, 2012) (Figure 1, see Figure legend for more details).
In line with this, here is now strong evidence demonstrating
that cerebral glucose consumption is not homogenous for all neu-
ral cell types and that metabolic specialization takes place in terms
of energy metabolism between neuron and glia (see e.g., Bélanger
et al., 2011a). Consistent with their higher energy requirements,
neurons sustain a high rate of oxidative metabolism compared
to glial cells (Lebon et al., 2002; Itoh et al., 2003; Bouzier-Sore
www.frontiersin.org February 2015 | Volume 9 | Article 23 | 1
Allaman et al. Glyoxalase system in the brain
FIGURE 1 | Schematic representation of the astrocyte-neuron lactate
shuttle (ANLS). Glutamate (Glu) released at the synapse activates
glutamatergic receptors (GluR) and is associated with important energy
expenditures in neuronal compartments. A large proportion of the glutamate
released at the synapse is taken up by astrocytes via excitatory amino acid
transporters (EAATs, more specifically GLT-1 and GLAST) together with 3 Na+
ions. This Na+ is extruded by the action of the Na+/K+ ATPase, consuming
ATP. This triggers non oxidative glucose utilization in astrocytes and glucose
uptake from the circulation through the glucose transporter GLUT1
expressed by both capillary endothelial cells and astrocytes.
Glycolytically-derived pyruvate is converted to lactate by lactate
dehydrogenase 5 (LDH5; mainly expressed in astrocytes) and shuttled to
neurons through monocarboxylate transporters (mainly MCT1 and MCT4 in
astrocytes and MCT2 in neurons). In neurons, this lactate can be used as an
energy substrate following its conversion to pyruvate by LDH1 (mainly
expressed in neurons). Neurons can also take up glucose via the neuronal
glucose transporter 3 (GLUT3). Concomitantly, astrocytes participate in the
recycling of synaptic glutamate via the glutamate-glutamine cycle. Following
its uptake by astrocytes, glutamate is converted to glutamine (Gln) by the
action of glutamine synthetase (GS) and shuttled to neurons where it is
converted back to glutamate by glutaminases (GLS). Reproduced with
permission from Bélanger et al. (2011a).
et al., 2006; Boumezbeur et al., 2010a). Interestingly, a large body
of evidence shows that neurons can efficiently use lactate as an
energy substrate (Schurr et al., 1997; Bouzier et al., 2000; Qu
et al., 2000; Serres et al., 2005; Boumezbeur et al., 2010b) and
even show a preference for lactate over glucose when both sub-
strates are present (Itoh et al., 2003; Bouzier-Sore et al., 2006).
By contrast, although astrocytes display lower rates of oxidative
metabolism compared to neurons, they avidly take up glucose
and characteristically present a high glycolytic rate (Itoh et al.,
2003; Herrero-Mendez et al., 2009; Bittner et al., 2010). A large
portion of the glucose entering the glycolytic pathway in astro-
cytes is released as lactate in the extracellular space (Pellerin and
Magistretti, 1994; Itoh et al., 2003; Serres et al., 2005; Bouzier-
Sore et al., 2006; Lovatt et al., 2007). Another striking differ-
ence between astrocytes and neurons is the presence of glycogen
reserves almost exclusively in the glial compartment, the mobi-
lization of which also leads to lactate release in the extracellular
space (see e.g., Dringen et al., 1993; Allaman, 2009; Bélanger et al.,
2011a). Even though the ANLS hypothesis is compatible with
some glucose utilization by neurons, it (the ANLS) has been chal-
lenged by some studies claiming that glucose is themain, if not the
exclusive, energy substrate for oxidative metabolism in neurons
(see e.g., Chih and Roberts, 2003; Hertz et al., 2007; Dienel, 2012;
Patel et al., 2014).
In addition to this, astrocytes are known to display high
metabolic plasticity in terms of glucose utilization, when com-
pared to neurons (Pellerin and Magistretti, 1994; Almeida et al.,
2001; Prapong et al., 2002; Porras et al., 2004; Gavillet et al., 2008;
Allaman et al., 2010; Belanger et al., 2010). One striking example
is the differential energetic response of astrocytes and neurons fol-
lowing the inhibition of mitochondrial respiration by nitric oxide
(NO). In neurons, NO induces a massive intracellular ATP deple-
tion and leads to apoptosis. By contrast, astrocytes respond to NO
by increasing their glycolysis rate, which restrains the fall in ATP
levels and prevents apoptosis (Almeida et al., 2001). A critical ele-
ment accounting for the glycolytic response in astrocytes is the
synthesis of fructose-2,6-bisphosphate—a potent activator of the
glycolytic enzyme phosphofructokinase-1—by the enzyme Pfkfb
(Almeida et al., 2004) (Figure 2). While Pfkfb is highly expressed
in astrocytes, it is virtually absent in neurons due to its constant
proteasomal degradation, therefore impeding glycolysis stimula-
tion in neurons (Herrero-Mendez et al., 2009). Nevertheless, the
ability of neurons to increase their glucose utilization rate in dif-
ferent conditions has also been described (see e.g., Dienel, 2012;
Frontiers in Neuroscience | Neuroenergetics, Nutrition and Brain Health February 2015 | Volume 9 | Article 23 | 2
Allaman et al. Glyoxalase system in the brain
FIGURE 2 | Schematic representation of the main metabolic pathways
involved in MG production and elimination. (A) MG is formed mainly by
the fragmentation of the glycolytic intermediates glyceraldehyde-3-phosphate
(Glyceraldehyde-3P) and dihydroxyacetone phosphate (DHAP), but also from
the metabolism of lipids and proteins (B). Phosphofructokinase-1 (PFK) is the
rate-limiting step of glycolysis and thus constitutes an important regulatory
site, one of its most potent allosteric activators being Fructose-2,
6-bisphosphate (Fructose-2,6-P2). Fructose-2,6-P2 levels are controlled by the
enzyme 6-phosphofructose-2-kinase/fructose-2,6-bisphosphatase (Pfkfb)
which is most abundantly expressed in astrocytes compared to neurons
(Herrero-Mendez et al., 2009). (C) MG is detoxified principally via the
glyoxalase system which consists of the enzymes Glyoxalase-1 (Glo-1) and
Glyoxalase-2 (Glo-2). The first step in MG detoxification requires its
spontaneous reaction with reduced glutathione (GSH) to form a hemithioacetal
which is used as a substrate by Glo-1 to form S-Lactoylglutathione. Glo-2 then
catalyzes the transformation of S-Lactoylglutathione into D-Lactate, recycling
GSH in the process. (D) The pentose phosphate pathway is linked to MG
detoxification via the formation of NADPH which is required for the recycling
of GSH from its oxidized form (GSSG) via the action of glutathione reductase
(GR). Reproduced with permission from Bélanger et al. (2011b).
Patel et al., 2014). The abovementioned observations, in con-
junction with transcriptome analysis of brain cells isolated by
fluorescence-activated cell sorting (FACS) revealing weaker and
differential expression of glycolytic enzymes in neurons than in
astrocytes (Lovatt et al., 2007; Cahoy et al., 2008; Zhang et al.,
2014), sustain the view of astrocytes as a prevalent site for the
glycolytic processing of glucose in the brain.
By opposition to one’s common belief, glycolysis is not an
innocuous metabolic pathway for cells, since it inevitably pro-
duces methylglyoxal (MG) as a by-product. The accumulation
of the cell-permeant MG is highly deleterious, since this com-
pound is one of the most potent glycating agents produced in
cells. It readily reacts with proteins, lipids and nucleic acids
to form advanced glycation end products (AGEs). AGEs are
implicated in various pathophysiological mechanisms, including
those associated with diabetic complications (cataracts, retinopa-
thy, nephropathy, angiopathy), aging, and neurodegenerative
disorders (Wautier and Guillausseau, 2001; Munch et al., 2012).
In normal conditions, MG detoxification is mainly achieved by
the ubiquitous enzymatic glyoxalase system that keeps MG con-
centration at low non-toxic cellular levels.
Since the brain has very high energy requirements in order to
maintain neural cells function, brain cells are more likely to be
exposed to MG compared with other cell types. Therefore, MG
handling by neural cells has to be tightly regulated in order to
prevent irreversible MG toxicity.
MG AND THE GLYOXALASE SYSTEM
MG, a dicarbonyl compound, is a ubiquitous product of cellular
metabolism being therefore present in all cells, either under nor-
mal or pathological conditions. Enzymatic and non-enzymatic
routes are known to produce MG. The rate of MG formation
depends on the organism, tissue, cell metabolism and physiologi-
cal conditions.
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While MG can be produced as a by-product of protein and
fatty acid metabolism (Thornalley, 1996; Kalapos, 1999; Vander
Jagt and Hunsaker, 2003), the glycolytic pathway represents the
most important endogenous source of MG via the fragmentation
of the triosephosphates glyceraldehyde-3-phosphate (GAP) and
dihydroxyacetone phosphate (DHAP) (Richard, 1993) (Figure 2).
It is estimated that 0.1–0.4% of the glycolytic flux results in MG
production (Kalapos, 2008a) and that nonenzymatic MG for-
mation rate, from GAP and DHAP, is 0.1mM per day in rat
tissues (Richard, 1991). Cerebrospinal fluid levels of MG have
been estimated to be between 10 and 20μM (Kuhla et al., 2005),
and cellular levels of free MG are typically in the low μM range
(Rabbani and Thornalley, 2010). Importantly, as MG is highly
reactive its half life is short in a biological environment and there-
fore, at the time and site of production local concentrations may
be significantly higher (Kalapos, 2008b). As an example of the
potency at which MG reacts with biological samples, addition
of 1μM [14C]MG to human plasma ex vivo produced complete
and irreversible binding of MG to plasma protein within 24 h at
37◦C (Thornalley, 2005). Consistently, up to 90–99% of cellular
MG is bound to macromolecules, and assessment of total (free +
bound) MG, suggested that cellular concentrations up to 300μM
can be reached (Thornalley, 1996; Chaplen et al., 1998).
High levels of MG occur when the concentrations of their pre-
cursors are elevated, such as in hyperglycemia, impaired glucose
utilization and triosephosphate isomerase deficiency (Ahmed
et al., 2003a).
As previously mentioned, MG is one of the most potent gly-
cating agents present in cells making its accumulation highly
deleterious. For instance, MG readily reacts with lipids, nucleic
acids and with lysine and arginine residues of proteins to form
AGEs such as argpyrimidine, hydroimidazolone MG-H1, MG-
derived lysine dimer and Nε-(1-carboxyethyl)lysine (Thornalley,
2005, 2007; Rabbani and Thornalley, 2010). Besides the direct
changes in protein function by MGmodifications, AGE-modified
proteins also exert cellular effects via their interaction with spe-
cific AGE receptors [RAGE (receptor for AGE)] (Grillo and
Colombatto, 2008; Daroux et al., 2010), which triggers an inflam-
matory response at the cellular level, also accounting for AGE
toxicity. AGEs play an important role in various pathophysi-
ological mechanisms, including those associated with diabetic
complications, aging, and neurodegenerative disorders (Wautier
and Guillausseau, 2001; Ramasamy et al., 2005; Goldin et al.,
2006; Munch et al., 2012).
In order to avoid the toxic effects of MG, cells possess different
detoxifying mechanisms such as the glyoxalase, aldose reduc-
tase, aldehyde dehydrogenase and carbonyl reductase pathways
(Thornalley, 1993; Kalapos, 1999; Vander Jagt and Hunsaker,
2003). Undoubtedly, the glyoxalase system, an ubiquitous enzy-
matic pathway, is the main detoxifying system for MG and
other reactive dicarbonyl compounds in eukaryotic cells, thereby
playing a major role the cellular defense against glycation and
oxidative stress (Thornalley, 1993; Kalapos, 2008b). It detoxi-
fies MG through two sequential enzymatic reactions catalyzed by
glyoxalase-1 (Glo-1) and glyoxalase-2 (Glo-2), using glutathione
as a co-factor. Glo-1 converts the hemithioacetal formed by the
non-enzymatic reaction of reduced glutathione (GSH) with MG,
to S-D-lactoylglutathione. This compound is then metabolized
to D-Lactate (the poorly metabolizable enantiomer of L-lactate)
by Glo-2, which recycles glutathione in the process (Figure 2)
(Thornalley, 1993). Since S-D-lactoylglutathione is a non-toxic
compound, metabolism of the dicarbonyl compound by Glo-1
represents a crucial step for MG detoxification, implying that
Glo-1 activity indirectly determines MG toxicity and the rate of
AGEs formation. One should also consider that GSH recycling
occurs as S-D-lactoylglutathione is metabolized to D-Lactate.
This implies that large increases ofMG levels or low Glo-2 activity
may result in S-D-lactoylglutathione accumulation, keeping GSH
trapped, hence potentially leading to decreased GSH availability
for other cellular processes such as defense against oxidative stress
(Dringen, 2000).
GLYOXALASE SYSTEM IN NEURONS AND ASTROCYTES
Direct assessment of the intrinsic glyoxalase system capacities in
both neurons and astrocytes has been done using mouse pri-
mary cortical cultures (Bélanger et al., 2011b). In this model,
both Glo-1 and Glo-2 enzymes activities are significantly higher
in astrocytes compared to neurons, i.e., Glo-1 andGlo-2 displayed
respectively 9.8 times higher and 2.5 higher activities in astrocytes
as compared to neurons.
In both cell types, Glo-1 activity rate was markedly higher
compared to Glo-2 supporting the view that the rapid conversion
of MG and GSH to S-D-Lactoylglutathione represents a criti-
cal step in the cellular defense against MG toxicity (Thornalley,
2008). A similar difference in the levels of Glo-1 and Glo-2 expres-
sion was also observed in C6 glioma cell lines (Hansen et al.,
2012). Consistent with the differential Glo-1 activity between
astrocytes and neurons, concentration-response curve analysis
demonstrated that astrocytes detoxify exogenously added MG to
D-lactate more efficiently than neurons (Bélanger et al., 2011b).
Glo-1 enrichment in astrocytes compared to neurons was con-
firmed in vivo in the cerebral cortex of mice by immunofluores-
cence labeling (Bélanger et al., 2011b). Consistent with in vitro
results, while Glo-1 immunoreactivity could be observed in both
astrocytes (GFAP-positive cells) and neurons (NeuN-positive
cells), the strongest levels of Glo-1 immunostaining was found in
GFAP-positive cells. At the structural level, Glo-1 immunoreactiv-
ity in astrocytes was observed to be present the cell body as well
as in the main astrocytic processes, i.e., along the GFAP-positive
filaments.
Consistent with this observation, cell specific FACS demon-
strated a 2-fold enrichment of Glo-1 activity in acutely isolated
brain cortical astrocytes compared to other brain cortical cells
(Bélanger et al., 2011b). Using a similar technique, Cahoy et al.
(2008) demonstrated a 2.5-fold enrichment of Glo-1 mRNA
expression in acutely isolated mouse astrocytes (Cahoy et al.,
2008). In the human brain samples, both Glo-1 positive astro-
cytes and neurons were observed (Chen et al., 2004; Kuhla et al.,
2006a).
Together, these results demonstrate a consistently highly effi-
cient glyoxalase system in (cortical) astrocytes compared to neu-
rons in both in vitro and in vivo situations. Moreover, this suggests
that such a cell-specific distribution has physiological significance
in the intact brain.
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EXOGENOUS MG IS HIGHLY TOXIC FOR NEURONS, RED-OX
DEPENDENCY
Consistent with a less active glyoxalase system, neurons are
more vulnerable than astrocytes to MG toxicity. Indeed, exoge-
nously added MG at concentrations between 250 and 750μM
is detrimental to neuronal viability in hippocampal, cortical and
primary sensory cortex cultures or in SH-SY5Y neuroblastoma
cells (Di et al., 2004, 2008; de Arriba et al., 2007; Bélanger
et al., 2011b; Radu et al., 2012), whereas concentrations up to
1mM do not impact cellular integrity in astrocytic cultures or
in C6 glioma cells (Bélanger et al., 2011b; Hansen et al., 2012).
Direct comparison of MG toxicity in primary cultures of mouse
cortical neurons and astrocytes evidenced a 6-fold higher suscep-
tibility toward MG toxicity in neurons compared to astrocytes
(Bélanger et al., 2011b). Even more strikingly, when co-cultured
with astrocytes neurons are significantly protected from MG
toxicity (added at concentration s of up to 2mM) further high-
lighting the high capacity of astrocytes to detoxify extracellular
sources of MG, protecting neurons in the process (Bélanger et al.,
2011b).
Neuronal MG toxicity is associated with AGEs production
and accumulation (Bélanger et al., 2011b) but is also involved
in oxidative stress-mediated cell death. Indeed, intracellular glu-
tathione and NADPH levels, as well as glutathione-dependent
antioxidant processes, are strongly decreased in cultured neu-
ronal cell preparation following MG application, leading to
cellular oxidative stress and intracellular accumulation of reac-
tive oxygen species (Di et al., 2004, 2008; de Arriba et al.,
2007). As an example, co-treatment of MG with the antiox-
idant, and glutathione precursor, N-acetylcysteine (NAC) pre-
vents MG-mediated neuronal death in hippocampal cultures
(Di et al., 2004). This can be explained by the requirement
of GSH for MG detoxification. Indeed, although GSH is recy-
cled back during the processing of MG though the glyoxalase
system at the Glo-2 step, exposure to MG is likely to cause
a transient GSH depletion since part of the intracellular GSH
is kept trapped in the form of S-D-lactoylglutathione dur-
ing the process, especially since Glo-2 displays much slower
activity rates than Glo-1 in both astrocytes and neurons (see
above) (Figure 2). This transient GSH depletion resulting from
glyoxalase system activity may therefore have important con-
sequences for the cell’s oxidative stress status [e.g., increas-
ing oxidized glutathione (GSSG)/GSH and NADP/NADPH
ratios], since glutathione represents one of the most impor-
tant antioxidants in mammalian cells (Dringen, 2000). In
line with this, GSSG was recently found to directly inacti-
vate Glo-1 through covalent modification (Birkenmeier et al.,
2010).
It has previously been reported that glutathione concentra-
tions are higher in astrocytes than in neurons (Dringen, 2000).
Such differences in glutathione metabolism, together with higher
Glo-1 and -2 activities, may explain the greater resistance of astro-
cytes against MG toxicity compared to neurons. In agreement
with this, astrocytes red-ox indexes (glutathione and NADPH
levels) were not severely compromised even when cultured astro-
cytes were exposed to milimolar concentrations of MG (Bélanger
et al., 2011b).
IMPACT OF MANIPULATING Glo-1 ACTIVITY IN
ASTROCYTES AND NEURONS
The observation that exogenous MG is highly damaging to neu-
rons compared to astrocytes raises the question of the capacity of
these cells to control intracellular MG production and detoxifica-
tion. Experiments conducted in vitro on neural cells in which Glo-
1 activity was decreased gave interesting clues about this question.
Using RNA interference strategies Bélanger and collaborators
observed that a similar decrease in Glo-1 activity (80%) does not
impact astrocytic and neuronal cell viability to the same extent
using primary mouse cortical cultures as a model (Bélanger et al.,
2011b). For instance, Glo-1 inhibition resulted in a significant loss
of neuronal viability (35%) that was associated with increased
AGEs accumulation, while no deleterious effects were measured
in astrocytes. Of note, due to the high Glo-1 expression levels in
astrocytes, a 80% decrease in Glo-1 expression in these cells leaves
Glo-1 expression at the same levels of expression than those mea-
sured in control neuronal cultures. This observation is consistent
with a study conducted on SH-SY5Y cells in which chronically
elevated MG concentrations induced by Glo-1 pharmacologi-
cal inhibition with p-bromobenzylglutathione cyclopentyl diester
(pBrBzGSCp2) also resulted in a decreased cellular viability (by
25%) (Kuhla et al., 2006b).
Considering the high susceptibility of neurons to Glo-1 silenc-
ing as described above, Bélanger et al. sought to determine
whether Glo-1 upregulation could conversely protect neurons
against various cellular stresses and in particular MG (Bélanger
et al., 2011b). Intriguingly, they did not observed significant pro-
tection of cultured cortical neurons against exogenous MG toxi-
city following lentiviral-mediated Glo-1 overexpression, despite a
large increase in enzymatic activity (6.8-fold increase). This result
suggests that low expression level of Glo-1 is not the only factor
accounting for the high neuronal vulnerability to MG toxicity. As
discussed above, cultured neurons display particularly low levels
of glutathione and a poor capacity to replenish the glutathione
pool following exposure to MG, which may also explain neu-
ronal susceptibility toward MG insults. Low glutathione levels
may therefore represent a limiting factor for MG detoxification
in neurons, in which case Glo-1 overexpression per se would not
be sufficient to provide neuroprotective properties.
INCREASED GLYCOLYSIS OVERWHELMS NEURONAL
GLYOXALASE SYSTEM CAPACITY
As previously stated, the poor capacity of neurons to upregulate
glycolysis (Almeida et al., 2001) is partially explained by the con-
stitutive downregulation of Pfkfb, more specifically Pfkfb3 also
known as PFK-2 isoform 3, which is responsible for the gener-
ation of fructose-2,6-bisphosphate, a key regulator of glycolysis
(Herrero-Mendez et al., 2009) (Figure 2). Considering that, as
described above, neurons have low MG detoxification capacity,
the low protein expression levels of Pfkfb3 may be viewed as a
neuronal regulatory mechanism preventing MG damages, since
MG production is tightly dependent upon the glycolytic rate. In
order to get insights about such hypothesis, Bélanger and collabo-
rators manipulated glucose utilization in neuronal cultures taking
advantage of the observation made by Herrero-Mendez and col-
laborators that overexpression of Pfkfb3 results in an increased
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glycolytic rate in cultured rat neurons (Herrero-Mendez et al.,
2009). In primary cultures of cortical neurons, it was observed
that increased lentiviral-mediated Pfkfb3 expression resulted in a
limited but significant stimulation of glucose utilization (20%)
(Bélanger et al., 2011b). Remarkably, this stimulation of the
neuronal glycolytic rate coincided with a significant increase in
intracellular MG levels and enhanced levels of argpyrimidine-
modified proteins, which are MG-specific AGE product. In this
context, it is worth mentioning that Herrero-Mendez and col-
laborators demonstrated in their initial work that an increase
in neuronal glycolytic rate (i.e., induced by Pfkfb3 overexpres-
sion) was accompanied by a marked decrease in the oxidation
of glucose through the pentose phosphate pathway (a metabolic
route involved in the regeneration of reduced glutathione through
the formation of reducing equivalent in the form of NADPH,
Figure 2). Hence, less NADPH is available to regenerate the small
pool of neuronal GSH, which may further compromise the effi-
ciency of the glyoxalase system (Herrero-Mendez et al., 2009).
Altogether, these results support the notion that even a modest
increase in neuronal glycolytic rate can readily overwhelm the
neuronal glyoxalase system, which results in the accumulation of
MG and thereupon in protein damage.
GLYOXALASE SYSTEM IN BRAIN DISORDERS
Historically, most research on the glyoxalase system in diseases
has focused on the importance of MG detoxification to prevent
cellular damage due to the glycation of proteins and nucleic acids.
These studies have implicated high concentrations of MG and/or
low Glo-1 activity in the etiology of metabolic disorders, such as
diabetes (Wautier and Guillausseau, 2001; Ramasamy et al., 2005;
Goldin et al., 2006).
When looking more specifically at pathologies affecting the
brain, modulations of the glyoxalase system have been observed in
aging as well as in various neuropathological conditions, includ-
ing ischemia, epilepsy, Alzheimer’s disease and Parkinson’s disease
(Ramasamy et al., 2005; Kuhla et al., 2007; Kurz et al., 2011;
Distler and Palmer, 2012). For instance, starting from the fifth
decade Glo-1 expression was reported to decrease progressively
in the human brain (Kuhla et al., 2006a), in correlation with
increased AGEs levels in neurons and astrocytes (Luth et al.,
2005). In line with this, over-expression of the Glo-1 homolog in
C. elegans (ortholog CeGly) decreasesMG-dependent toxic effects
associated with the loss Glo-1 activity that occurs with age, and
prolonged C. elegans life span (Morcos et al., 2008). Incidentally,
decrease in glutathione levels during aging may also exacerbate
the deleterious effects of declining Glo-1 expression (Currais and
Maher, 2013). In line with this, the concentration of GSH in
human lenses decreases with age (Kamei, 1993) which correlates
with an increase of the MG-related AGE content (Ahmed et al.,
2003b). Hence, reduced levels of glutathione in aging may not
only have consequences for its function as an antioxidant, i.e.,
red-ox defense mechanisms, but also for its role as co-factor of
the glyoxalase system (Currais and Maher, 2013).
As mentioned, impaired Glo-1 activity also contributes to
the pathogenesis of neurodegenerative disorders. MG accumu-
lation is tightly linked oxidative stress and AGE formation,
which are major factors involved in many of these age-dependent
pathologies. In Alzheimer’s disease (AD), a marked increase in
AGE accumulation is observed at later stages, which correlates
with a decrease below normal levels of Glo-1 (Luth et al., 2005;
Kuhla et al., 2007). In line with this, cerebrospinal fluid of patients
affected by AD presents high levels of MG (Kuhla et al., 2005). A
striking observation is the co-localization of AGEs with amyloid-β
plaques and neurons containing hyperphosphorylated tau in AD
brains, while astrocytes are also affected as they show increased
AGE levels (Wong et al., 2001; Luth et al., 2005). Such observa-
tions suggest an impairment of the glyoxalase system in ADwhich
may be involved in the vicious circle of amyloid-β deposition,
AGE formation and oxidative stress associated with this disease.
Nevertheless, further studies are required to delineate the spe-
cific effects of the glyoxalase system alteration on different neural
cell types. Glo-1 expression was also shown to be modulated in
ischemia. Indeed, following permanent middle cerebral artery
occlusion, temporal and spatial changes in Glo-1 immunoreac-
tivity in endothelial cells, neurons and astrocytes were observed
(Pieroh et al., 2014).
Interestingly, higher levels of baseline MG derivatives in the
serum were associated with a faster rate of cognitive decline in
ederly individuals, indicating that peripheral MG metabolism
imbalances may also affect brain pathopysiology (Beeri et al.,
2011).
The functional defense role of the glyoxalase pathway has
been exploited as a potential therapeutic target, through strate-
gies aiming at reducing MG concentrations and/or enhancing the
glyoxalase system in brain diseases. For example, More and col-
laborators developed a synthetic co-factor for Glo-1 (ψ-GSH)
that crosses the blood brain barrier (BBB) (More et al., 2013).
This molecule was shown to mitigate Alzheimer’s disease indi-
cators in a transgenic mouse model (APP/PS1). For instance,
it was observed that intraperitoneal administration of ψ-GSH
completely averts the development of spatial mnemonic and long-
term cognitive/cued-recall impairment in these mice. Moreover,
amyloid-β deposition and oxidative stress indicators were also
drastically reduced in the ψ-GSH-treated APP/PS1 mouse. While
a detailed characterization of the selectivity of ψ-GSH mode of
action in vivo remains to be fully established, ψ-GSH represents
a promising drug for the treatment of diseases associated with a
glyoxalase dysfunction, including neurodegenerative pathologies.
Increasing Glo activities in ischemia has also been shown to be an
effective neuroprotective strategy. In a recent study, Glo proteins
were coupled to the Tat (transactivator of transcription) peptide
as a vehicle to provide Glo-1 and Glo-2 exogenously to cells of the
central nervous system (Shin et al., 2014). These Tat–Glo proteins
were intraperitoneally injected 30min before performing tran-
sient forebrain ischaemia in gerbils. Increased intracerebral Glo
levels were detected, indicating the ability of the agent to cross
the BBB. Importantly, cell viability tests performed 7 and 14 days
after ischaemia, demonstrated a neuroprotective effect of Tat-Glo
proteins delivery. Interestingly, it was noted that enhancing the
glyoxalase system as a whole via the simultaneous injection of
Tat–Glo-1 and Tat–Glo-2 displayed the highest protection level.
Such examples demonstrate the importance of the glyoxalase
dysfunction in AD and ischemia, but also represent a proof of
concept for the development of strategies aiming to improve the
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efficiency or restore the glyoxalase defense system in the context
of brain disorders.
Finally, recent studies from several laboratories also suggested
that modulations of MG concentration and Glo-1 activity are
involved in schizophrenia, autism, anxiety, depression, sleep and
pain phenotypes (Hambsch et al., 2010; Bierhaus et al., 2012;
Distler and Palmer, 2012; Distler et al., 2012, 2013; Jakubcakova
et al., 2013), further pointing to the role of the glyoxalase system
as an important element in brain physiology and pathology.
PHYSIOLOGICAL ROLES OF MG AND THE GLYOXALASE
SYSTEM
The glutathione dependence as a co-factor for Glo-1, the non-
enzymatic origin of MG from triosephosphates and the fact that
the end-product is D- rather than L-lactate, isolate MG and Glo-
(1 and 2) from glycolysis, leaving this system orphan in function.
So is there any physiological cerebral function for this path-
way, apart from its importance as a detoxifying system? There
is now emerging evidence that the answer is yes. For instance,
modulation of Glo-1 activity was shown to regulate anxiety-
like behavior and seizure-susceptibility in mice. These effects are
likely to be mediated through the regulation of MG levels, as
MG was demonstrated to act as a competitive partial agonist for
GABAA (γ -aminobutyric acid A) receptors (Distler et al., 2012;
McMurray et al., 2014). MG was also shown to modulate the
activities other proteins such as the voltage-gated sodium chan-
nel Nav1.8 or the TRPA1 ion channel (Bierhaus et al., 2012;
Andersson et al., 2013). In a recent study, it was shown that D-
lactate supports the viability of dopaminergic neurons in vitro by
promoting the maintenance of mitochondrial potential (Toyoda
et al., 2014). Interestingly, the latter work was linked to the dis-
covery of DJ-1 (also known as PARK7) as a human homolog of a
novel type of glyoxalase (Glo-3), that converts MG to lactic acid
in the absence of glutathione (Lee et al., 2012; Toyoda et al., 2014).
DJ-1 has been linked with the onset of Parkinson’s disease, which
is associated with mitochondrial decline in dopaminergic neu-
rons of the substantia nigra, suggesting a possible mitochondrial
regulatory role of MG metabolism in dopaminergic neurons.
CONCLUDING REMARKS
Altogether, the observations reviewed in this article support the
notion that there are major differences in the glyoxalase system
of astrocytes and neurons, which impact their respective capac-
ity for cellular defense against glycation. As they are mainly based
on in vitro observations, these findings remain to be fully estab-
lished in the in vivo situation. Nevertheless, there is converging
and convincing evidence demonstrating that astrocytes display a
muchmore efficient glyoxalase system than neurons in cultures as
well as higher Glo-1 immunoreactivity and activity in the mouse
brain (Bélanger et al., 2011b). Interestingly, when compared to
the high MG-producing CHO cells or various other cell types
(Ranganathan et al., 1995; Shinohara et al., 1998; Wu et al., 2001;
Ahmed et al., 2003a; Kumagai et al., 2009), Glo-1 activity rates in
cultured astrocytic (Bélanger et al., 2011b) were shown to be sev-
eral fold higher, supporting the notion of a particularly efficient
glyoxalase system in astrocytes.
As previously mentioned, glutathione levels are significantly
higher in astrocytes than in neurons (Dringen, 2000; Bélanger
et al., 2011b). Since MG detoxification via the glyoxalase path-
way requires glutathione as a co-factor, these differences in glu-
tathione metabolism, together with a higher glyoxalase activity,
endow astrocytes with a optimized glyoxalase machinery and
thus a greater resistance to exogenous MG compared to neurons.
Consistently, numerous studies demonstrated a high neuronal
susceptibility to MG toxicity, which was associated with AGEs
production and oxidative stress leading to apoptosis (Kikuchi
et al., 1999; Di et al., 2004; Di Loreto et al., 2008; Chen et al.,
2010; Bélanger et al., 2011b; Radu et al., 2012).
The differential Glo-1 activity observed in astrocytes and neu-
rons may be linked to their dissimilar metabolic energetic profile.
As previously mentioned, astrocytes display high metabolic plas-
ticity in terms of glucose utilization, when compared to neurons
(Pellerin and Magistretti, 1994; Almeida et al., 2001; Prapong
et al., 2002; Porras et al., 2004; Gavillet et al., 2008; Allaman et al.,
2010; Belanger et al., 2010). In particular, astrocytes, are able to
up-regulate their glycolytic rate upon the synthesis of fructose-
2,6-bisphosphate by the enzyme Pfkfb3 (Almeida et al., 2004), an
enzyme that is virtually absent in neurons due to its constant pro-
teasomal degradation (Herrero-Mendez et al., 2009). Strikingly,
enhancing neuronal glycolysis via Pfkfb3 overexpression leads
to oxidative stress and apoptosis (Herrero-Mendez et al., 2009).
The observation that even a moderate increase in neuronal gly-
colysis, subsequent to Pfkfb3 overexpression, was sufficient to
significantly increase MG and AGEs levels (Bélanger et al., 2011b)
indicates a role of MG production in the neuronal toxicity asso-
ciated with an increase in the glycolytic rate. Hence, one can
conceive that neurons constitutively suppress pathways poten-
tially leading to MG formation because of their limited capacity
to face deleterious dicarbonyl stress. Similarly to Pfkfb, expres-
sion of the enzymatic machinery for glycogen synthesis is tightly
suppressed in neuron, explaining the virtual absence of glycogen
in this cell type. Importantly, failure to down regulate glycogen
synthesis machinery results in neuronal apoptosis (Vilchez et al.,
2007). Therefore, glycolysis and glycogen metabolism pathways
both of which are directly linked to triosephosphates metabolism
are tightly repressed in neurons and lead to apoptosis if activated.
These observations may explain why astrocyte can sustain a
higher basal glycolytic rate than neurons. They may also provide
insights into the reason why neurons depend on astrocytes-
derived lactate to satisfy their energy needs, as proposed by the
ANLS model and substantiated by several in vitro, ex vivo, and
in vivo data (Kasischke et al., 2004; Porras et al., 2004; Rouach
et al., 2008; Magistretti, 2009; Chuquet et al., 2010). Considering
that glucosemetabolism inevitably leads toMG formation, lactate
utilization may provide a mean for neurons to limit MG toxicity
by reducing their glucose utilization.
According to this hypothesis, neurons meet their high ener-
getic requirements by utilizing astrocyte-derived lactate (pro-
duced from extracellular glucose or glycogen pools), which can
be oxidized in the TCA cycle following its conversion to pyru-
vate. Such a scenario allows neurons to generate energy on
demand without compromising their antioxidant status (through
the mobilization of GSH by Glo-1), and leaves astrocytes with
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FIGURE 3 | Schematic representation of the proposed mechanism by
which higher glycolytic rates in astrocytes may provide a
mechanism limiting MG toxicity in neurons. Glycolysis in both
astrocytes and neurons leads to the production of the toxic MG
by-product. MG is detoxified by both cell types through the glyoxalase
system (GLO), producing D-lactate (D-lac). In normal and stimulated
conditions (ANLS) glucose utilization and its processing through the
glycolysis is tilted toward astrocytes, which release L-lactate (lactate)
that can be used by neurons as a mitochondrial energy substrate. Due
to the high activity of the MG-detoxifying glyoxalase system in
astrocytes, these cells are well equipped to handle MG accumulation
and toxicity. Because they display lower glyoxalase system activity,
neurons benefit from the glycolytic processing of glucose in astrocytes
since they are spared from: (1) MG accumulation and toxicity (2)
alterations in their antioxidant status (through the mobilization of GSH
by Glo-1), and (3) the burden of mounting an enzymatic system to
process MG. See text for more details. Green arrows highlight the
prevalent routes of glucose utilization in brain cells.
most of the MG burden (Figure 3). In line with this, the obser-
vation that astrocytes protect neurons against MG toxicity in
a co-culture model (Bélanger et al., 2011b), suggests another
level of astrocyte-neuron cooperativity. For instance, a highly
efficient glyoxalase system in astrocytes may reinforce neuronal
protection against MG potentially leaking from the periphery, the
cerebrospinal fluid or surrounding cells. As a whole, such view
support the concept of an “outsourced glycolysis” to astrocytes in
the brain as suggested by Barros (2013).
Interestingly, evidence shows that in astrocytes, genes
involved in glycogen, glycolysis and glutamate uptake are
expressed through a common metabolic program (Brunet et al.,
2010; Mamczur et al., 2014). Similarly, the expression of
genes involved in glutathione metabolism together with Glo-1
appears to be under the control of Nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) that is highly expressed in astrocytes
(Thimmulappa et al., 2002; Vargas and Johnson, 2009; Xue
et al., 2012). This further supports the notion of a differen-
tial, complementary and coherent metabolic phenotypic dif-
ferentiation between astrocytes and neurons with regards to
neuroenergetics.
Consistent with its important role in controlling MG detox-
ification, glyoxalase system dysfunctions have been associated
with various brain pathologies and in particular neurodegen-
erative diseases (Ramasamy et al., 2005; Kuhla et al., 2007;
Kurz et al., 2011; Distler and Palmer, 2012). Astrocytes are key
players in the maintenance of brain homeostasis, and several
cooperative metabolic processes between astrocytes and neurons
have been identified (Belanger and Magistretti, 2009; Allaman
et al., 2011), which include among others energy substrate deliv-
ery (e.g., ANLS), defense against oxidative stress and excitotox-
icity (Rothstein et al., 1996; Johnson et al., 2008; Vargas and
Johnson, 2009; Bélanger et al., 2011a; Pellerin and Magistretti,
2012). Therefore, glyoxalase system dysfunctions may not only
impact neuronal viability directly (if occurring in neurons) but
also indirectly (if occurring in astrocytes) through the alter-
ations of cooperative processes between astrocytes and neurons.
As exemplified with ψ-GSH and Tat-Glo delivery in the context
of AD and ischemia, strategies aiming to re-establish or boost the
glyoxalase system efficiency will therefore represent potentially
powerful therapeutically approaches for MG-associated brain
pathologies.
It can be concluded that there is now strong evidence show-
ing that the glyoxalase pathway differs significantly between
astrocytes and neurons in a way that renders neurons more
vulnerable to MG and AGE accumulation. These observations
pinpoint the notion that a metabolic specialization is tak-
ing place in brain cells, i.e., astrocytes being more glycolytic
than neurons, which may help protecting neurons from MG
toxicity. Moreover, more than being a dead-end pathway the
glyoxalase system may be important in the regulation of cere-
bral functions. Undoubtedly, future studies will help to shed
light of the importance of this system in brain physiology and
pathophysiology.
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